Prognostic Value of the Gustave Roussy Immune Score in Lung Cancer: A Meta-Analysis.

IF 2 4区医学 Q3 NUTRITION & DIETETICS

Nutrition and Cancer-An International Journal Pub Date : 2024-01-01 Epub Date: 2024-06-06 DOI:10.1080/01635581.2024.2361508

Yanli Ji, Wenping Wang

{"title":"Prognostic Value of the Gustave Roussy Immune Score in Lung Cancer: A Meta-Analysis.","authors":"Yanli Ji, Wenping Wang","doi":"10.1080/01635581.2024.2361508","DOIUrl":null,"url":null,"abstract":"Purpose: To clarify the prognostic role of the Gustave Roussy immune (GRIm) score in lung cancer.Methods: The PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases were searched up to March 30, 2024. The primary outcomes included overall survival (OS) and progression-free survival (PFS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the associations between the GRIm score and survival, and subgroup analyses were performed based on pathological type (non-small cell lung cancer vs. small cell lung cancer), tumor stage (advanced vs. limited stage) and treatment approach (immune checkpoint inhibitor vs. surgery vs. chemotherapy).Results: Eight studies with 1,333 participants were included. The pooled results showed that a higher GRIm score predicted worse OS (HR = 1.96, 95% CI: 1.54-2.49, P < 0.001) and PFS (HR = 1.64, 95% CI: 1.22-2.21, P = 0.001). Subgroup analyses for OS and PFS showed similar results. However, subgroup analyses for PFS indicated that the association between the GRIm score and PFS was nonsignificant among patients with small cell lung cancer (P = 0.114) and among patients treated with chemotherapy (P = 0.276).Conclusion: The GRIm score might serve as a novel prognostic factor for lung cancer. Additional studies are still needed to verify these findings.","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"707-716"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and Cancer-An International Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01635581.2024.2361508","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To clarify the prognostic role of the Gustave Roussy immune (GRIm) score in lung cancer.

Methods: The PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases were searched up to March 30, 2024. The primary outcomes included overall survival (OS) and progression-free survival (PFS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the associations between the GRIm score and survival, and subgroup analyses were performed based on pathological type (non-small cell lung cancer vs. small cell lung cancer), tumor stage (advanced vs. limited stage) and treatment approach (immune checkpoint inhibitor vs. surgery vs. chemotherapy).

Results: Eight studies with 1,333 participants were included. The pooled results showed that a higher GRIm score predicted worse OS (HR = 1.96, 95% CI: 1.54-2.49, P < 0.001) and PFS (HR = 1.64, 95% CI: 1.22-2.21, P = 0.001). Subgroup analyses for OS and PFS showed similar results. However, subgroup analyses for PFS indicated that the association between the GRIm score and PFS was nonsignificant among patients with small cell lung cancer (P = 0.114) and among patients treated with chemotherapy (P = 0.276).

Conclusion: The GRIm score might serve as a novel prognostic factor for lung cancer. Additional studies are still needed to verify these findings.

查看原文本刊更多论文

Gustave Roussy 免疫评分在肺癌中的预后价值：一项元分析

目的：阐明Gustave Roussy免疫（GRIm）评分在肺癌预后中的作用：方法：检索了截至2024年3月30日的PubMed、Embase、Web of Science和中国国家知识基础设施数据库。主要结果包括总生存期（OS）和无进展生存期（PFS）。根据病理类型（非小细胞肺癌 vs. 小细胞肺癌）、肿瘤分期（晚期 vs. 局限期）和治疗方法（免疫检查点抑制剂 vs. 手术 vs. 化疗）进行亚组分析：结果：共纳入八项研究，1,333 名参与者。汇总结果显示，GRIm得分越高，预示着OS越差（HR = 1.96，95% CI：1.54-2.49，P = 0.001）。OS 和 PFS 的亚组分析显示了相似的结果。然而，PFS的亚组分析表明，在小细胞肺癌患者（P = 0.114）和接受化疗的患者（P = 0.276）中，GRIm评分与PFS之间的关系不显著：结论：GRIm评分可作为肺癌的新型预后因素。结论：GRIm评分可作为肺癌的新型预后因素，但仍需更多研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition and Cancer-An International Journal 医学-营养学

CiteScore

5.80

自引率

3.40%

发文量

172

审稿时长

3 months

期刊介绍： This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies.